Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M

Actinium Pharmaceuticals (NYSE:ATNM) announced that the Company is initiating a new clinical trial that will study Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia.

As quoted in the press release:

Dr. Mark Berger, Actinium’s Chief Medical Officer said, “Relapsed and refractory AML patients unfortunately have limited treatment options that have little clinical benefit for patients.  Actimab-A is ideally suited to be studied in combination with other therapeutic modalities like CLAG-M given its potency and minimal extramedullary toxicities.  We are optimistic that this novel combination will demonstrate Actimab-A’ s key strengths through higher response rates, a greater number of patients successfully receiving a bone marrow transplant and ultimately, survival.  Further, it will demonstrate the value of using Actimab-A in combinations as we believe that combination therapies will be the next wave in the treatment of patients with AML just as combinations of regimen’s approved in multiple myeloma over the past three or four years have become for patients with that disease.”

Click here to read the full press release.